NBIX 13F Hedge Fund and Asset Management Owners

Data based on most recent fiscal year report
Market Cap	6.834 Billion	Shares Outstanding	88.49 Million	Avg Volume	1.648 Million
1-Yr BETA vs S&P TR	1.173	Current Ratio	10.2	Quick Ratio	10.2

View SEC Filings from NBIX instead.

Q4 2018	All Institutions	Hedge Funds ¹
To trade NBIX now:
Filers who had this stock in their top 10:	9	6 (0.6%)
13F Filers holding this stock:	314	55 (5.5%)
Aggregate 13F shares on 12/31/2018:	89.522 Million	13.288 Million
Aggregate 13F shares on 09/30/2018:	87.812 Million	13.14 Million
Percent change:	1.95%	1.13%
Funds creating new positions:	69	14
Funds Adding to an existing position:	107	19
Funds closing out their position:	86	18
Funds reducing their position:	110	18
¹ hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Neurocrine Biosciences Inc. Chart by YCharts

Yahoo! Finance

finviz

Check out our reporting and analysis

Dr. Michael J. Burry, the flawed genius profiled in The Big Short, just released his Scion Fund's first portfolio filing in two years. It holds some surprises.
via whalewisdomalpha 02/15/2019
Long-time Plantronics insider buys $1.15 million of stock after PLT’s earnings beat.
via whalewisdomalpha 02/14/2019
Bill Stiritz buys Post Holdings Inc. and exercises options, increasing his position by $54 million.
via whalewisdomalpha 02/11/2019
Dan Loeb’s Third Point Liquidates 3 Big Positions 02/11/2019
Ken Langone, multi-billionaire co-founder of Home Depot, buys $850K of Unifi, Inc.
via whalewisdomalpha 02/08/2019
Investors Bet Big on Redfin for Housing Recovery 02/04/2019
SendGrid Shares Sky Rocket On Hopes For Huge Growth 01/28/2019
Boeing’s Stock May Prove to be a Lucrative Bet 01/22/2019

Funds Holding NBIX (via 13F filings)

Quarter to view: Refresh Download CSV Download Excel (.xlsx) Download TSV

Click for Additional Filters

Market Value:

Ranking:

% of portfolio

Exclude:

Exclude PRN

Refresh

*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

31.2 Thousand total shares from 27 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name	Type	Last Reported Shares Held	Last Reported Date	Filings in past year
SANDROCK ALFRED EVP, CHIEF MEDICAL OFFICER	Officer	8,753	2019-02-12	1
ABERNETHY MATT CHIEF FINANCIAL OFFICER	Officer	0	2019-02-07	2
ROBERTS EIRY CHIEF MEDICAL OFFICER	Officer	0	2019-02-07	2
GORMAN KEVIN CHARLES CHIEF EXECUTIVE OFFICER	Officer Director	417,597	2019-02-06	4
BOZIGIAN HAIG P. CHIEF DEVELOPMENT OFFICER	Officer	141,639	2019-02-06	5
GRIGORIADIS DIMITRI E. CHIEF RESEARCH OFFICER	Officer	120,065	2019-02-06	6
GANO KYLE CHIEF BUSINESS DEVELOPMENT OFF	Officer	85,833	2019-02-06	4
LLOYD-SMITH MALCOLM CHIEF REGULATORY OFFICER	Officer	19,238	2019-02-06	3
LIPPOLDT DARIN CHIEF LEGAL OFFICER	Officer	19,646	2019-02-06	3
BENEVICH ERIC CHIEF COMMERCIAL OFFICER	Officer	20,745	2019-02-06	3
NEVINNY CORINNE H	Director	0	2019-01-25	3
POPS RICHARD F	Director	32,500	2019-01-25	5
RASTETTER WILLIAM H	Director	79,672	2018-11-12	1
LYONS GARY A	Director	245,697	2018-11-02	4
SHERWIN STEPHEN A	Director	5,164	2018-10-31	3
ROBERTS BRYAN E	Director 10% Owner	5,332,377	2018-06-20	0
MORROW GEORGE J	Director	0	2018-05-24	1
COUGHLIN TIMOTHY P	Director	0	2018-05-15	0
HOVE ANDERS D	Director	0	2018-03-01	0
OBRIEN CHRISTOPHER FLINT FORMER CHIEF MEDICAL OFFICER	Officer	55,946	2018-02-05	0
BVF PARTNERS L P/IL BIOTECHNOLOGY VALUE FUND L P BIOTECHNOLOGY VALUE FUND II LP BVF INVESTMENTS LLC BVF INC/IL LAMPERT MARK N	SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES	No longer subject to file	2017-07-14	0
MOLLICA JOSEPH A	Director	0	2017-05-22	0
GROS DAVID-ALEXANDRE C PRESIDENT & COO	Officer	0	2017-02-06	0
VALEUR JENSEN MARGARET E GENERAL COUNSEL	Officer	100,000	2016-02-01	0
MITCHELL W THOMAS	Director	1,000	2015-06-23	0
NEUROCRINE BIOSCIENCES INC	Director	16,030	2015-04-07	0
VALE WYLIE W	Director	0	2011-05-25	0
VENROCK HEALTHCARE CAPITAL PARTNERS LP VHCP CO-INVESTMENT HOLDINGS, LLC VHCP MANAGEMENT, LLC HOVE ANDERS D ROBERTS BRYAN E	10% Owner	5,114,934	2011-02-02	0
BVF PARTNERS L P/IL BIOTECHNOLOGY VALUE FUND L P BIOTECHNOLOGY VALUE FUND II LP BVF INVESTMENTS LLC BVF INC/IL	10% Owner INDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNER	25,254,628	2009-06-03	0

Insider Transactions Last 60 Days

Reporting Owners	Transaction Date	Transaction Code	Shares	Share Price	Acquired or Disposed	Shares Owned Following Transaction	Combined shares owned after filing	Direct/Indirect Ownership	10b-5
BENEVICH ERIC - Officer CHIEF COMMERCIAL OFFICER	2019-02-07	A	15,423		a	15,423	20,745.00	direct
GORMAN KEVIN CHARLES - Director - Officer CHIEF EXECUTIVE OFFICER	2019-02-07	A	24,677		a	24,677	417,597.00	direct
LLOYD-SMITH MALCOLM - Officer CHIEF REGULATORY OFFICER	2019-02-07	A	7,712		a	7,712	19,238.00	direct
LIPPOLDT DARIN - Officer CHIEF LEGAL OFFICER	2019-02-07	A	62,506		a	62,506	19,646.00	direct
ROBERTS EIRY - Officer CHIEF MEDICAL OFFICER	2019-02-07	A	12,339		a	12,339	0.00	direct
GRIGORIADIS DIMITRI E. - Officer CHIEF RESEARCH OFFICER	2019-02-07	A	9,254		a	9,254	120,065.00	direct
GANO KYLE - Officer CHIEF BUSINESS DEVELOPMENT OFF	2019-02-07	A	12,339		a	12,339	85,833.00	direct
BENEVICH ERIC - Officer CHIEF COMMERCIAL OFFICER	2019-02-07	A	83,341		a	83,341	20,745.00	direct
GORMAN KEVIN CHARLES - Director - Officer CHIEF EXECUTIVE OFFICER	2019-02-07	A	133,345		a	133,345	417,597.00	direct
ABERNETHY MATT - Officer CHIEF FINANCIAL OFFICER	2019-02-07	A	15,423		a	15,423	0.00	direct
LLOYD-SMITH MALCOLM - Officer CHIEF REGULATORY OFFICER	2019-02-07	A	41,671		a	41,671	19,238.00	direct
BOZIGIAN HAIG P. - Officer CHIEF DEVELOPMENT OFFICER	2019-02-07	A	12,339		a	12,339	141,639.00	direct
ROBERTS EIRY - Officer CHIEF MEDICAL OFFICER	2019-02-07	A	66,673		a	66,673	0.00	direct
GRIGORIADIS DIMITRI E. - Officer CHIEF RESEARCH OFFICER	2019-02-07	A	50,005		a	50,005	120,065.00	direct
GANO KYLE - Officer CHIEF BUSINESS DEVELOPMENT OFF	2019-02-07	A	66,673		a	66,673	85,833.00	direct
LIPPOLDT DARIN - Officer CHIEF LEGAL OFFICER	2019-02-07	A	11,567		a	11,567	19,646.00	direct
ABERNETHY MATT - Officer CHIEF FINANCIAL OFFICER	2019-02-07	A	83,341		a	83,341	0.00	direct
BOZIGIAN HAIG P. - Officer CHIEF DEVELOPMENT OFFICER	2019-02-07	A	66,673		a	66,673	141,639.00	direct
GRIGORIADIS DIMITRI E. - Officer CHIEF RESEARCH OFFICER	2019-02-06	S	531	$84.03	d	120,065	120,065.00	direct	yes
GANO KYLE - Officer CHIEF BUSINESS DEVELOPMENT OFF	2019-02-06	S	762	$83.56	d	85,833	85,833.00	direct	yes
BOZIGIAN HAIG P. - Officer CHIEF DEVELOPMENT OFFICER	2019-02-06	S	920	$83.54	d	141,639	141,639.00	direct	yes
LIPPOLDT DARIN - Officer CHIEF LEGAL OFFICER	2019-02-06	S	791	$83.52	d	19,646	19,646.00	direct	yes
BENEVICH ERIC - Officer CHIEF COMMERCIAL OFFICER	2019-02-06	S	920	$83.57	d	20,745	20,745.00	direct	yes
GORMAN KEVIN CHARLES - Director - Officer CHIEF EXECUTIVE OFFICER	2019-02-06	S	4,096	$84.23	d	417,597	417,597.00	direct	yes
LLOYD-SMITH MALCOLM - Officer CHIEF REGULATORY OFFICER	2019-02-06	S	920	$83.58	d	19,238	19,238.00	direct	yes
LLOYD-SMITH MALCOLM - Officer CHIEF REGULATORY OFFICER	2019-02-05	S	603	$88.13	d	17,508	17,508.00	direct	yes
GRIGORIADIS DIMITRI E. - Officer CHIEF RESEARCH OFFICER	2019-02-05	S	669	$88.17	d	118,322	119,071.00	direct	yes
BOZIGIAN HAIG P. - Officer CHIEF DEVELOPMENT OFFICER	2019-02-05	S	465	$88.06	d	138,244	139,909.00	direct	yes
LIPPOLDT DARIN - Officer CHIEF LEGAL OFFICER	2019-02-05	S	470	$88.11	d	18,162	18,162.00	direct	yes
GANO KYLE - Officer CHIEF BUSINESS DEVELOPMENT OFF	2019-02-05	S	1,300	$88.14	d	83,439	84,695.00	direct	yes
BENEVICH ERIC - Officer CHIEF COMMERCIAL OFFICER	2019-02-05	S	602	$88.08	d	17,595	19,015.00	direct	yes
LLOYD-SMITH MALCOLM - Officer CHIEF REGULATORY OFFICER	2019-02-05	S	669	$88.16	d	16,574	17,508.00	direct	yes
GORMAN KEVIN CHARLES - Director - Officer CHIEF EXECUTIVE OFFICER	2019-02-05	S	1,992	$88.28	d	413,943	413,943.00	direct	yes
LIPPOLDT DARIN - Officer CHIEF LEGAL OFFICER	2019-02-05	S	755	$88.08	d	17,482	18,162.00	direct	yes
GANO KYLE - Officer CHIEF BUSINESS DEVELOPMENT OFF	2019-02-05	S	465	$88.05	d	80,989	84,695.00	direct	yes
GRIGORIADIS DIMITRI E. - Officer CHIEF RESEARCH OFFICER	2019-02-05	S	401	$88.17	d	119,071	119,071.00	direct	yes
BOZIGIAN HAIG P. - Officer CHIEF DEVELOPMENT OFFICER	2019-02-05	S	885	$88.18	d	139,909	139,909.00	direct	yes
GANO KYLE - Officer CHIEF BUSINESS DEVELOPMENT OFF	2019-02-05	S	669	$88.14	d	84,695	84,695.00	direct	yes
GORMAN KEVIN CHARLES - Director - Officer CHIEF EXECUTIVE OFFICER	2019-02-05	S	2,497	$88.12	d	410,185	413,943.00	direct	yes
BENEVICH ERIC - Officer CHIEF COMMERCIAL OFFICER	2019-02-05	S	755	$87.95	d	19,015	19,015.00	direct	yes
GANO KYLE - Officer CHIEF BUSINESS DEVELOPMENT OFF	2019-02-04	S	1,375	$88.14	d	80,117	84,695.00	direct	yes
GORMAN KEVIN CHARLES - Director - Officer CHIEF EXECUTIVE OFFICER	2019-02-04	S	3,125	$88.10	d	408,082	413,943.00	direct	yes
GRIGORIADIS DIMITRI E. - Officer CHIEF RESEARCH OFFICER	2019-02-04	S	1,375	$88.12	d	117,066	119,071.00	direct	yes
BOZIGIAN HAIG P. - Officer CHIEF DEVELOPMENT OFFICER	2019-02-04	S	1,375	$88.10	d	137,372	139,909.00	direct	yes
ROBERTS EIRY - Officer CHIEF MEDICAL OFFICER	2019-01-08	S	1,857	$84.09	d	3,143	3,143.00	direct	yes

Click here to report any possible errors with this stock listing.

Neurocrine Biosciences Inc. (NBIX)

Check out our reporting and analysis

Funds Holding NBIX (via 13F filings)

Filter by:

Exclude:

Active Schedule 13D and 13G filings

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

Open Market Sells (S)

Exercise Derivative Conversion (M)

Current/Former Insiders

Insider Transactions Last 60 Days

Elevate your investments

Neurocrine Biosciences Inc. (NBIX)

Check out our reporting and analysis

Funds Holding NBIX (via 13F filings)

Filter by:

Exclude:

Active Schedule 13D and 13G filings

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

Open Market Sells (S)

Exercise Derivative Conversion (M)

Current/Former Insiders

Insider Transactions Last 60 Days

Report an error

Elevate your investments